Resonance Health Ltd. advised that Mr. Aaron Brinkworth has been appointed as Non-executive Director of the Company. Mr. Brinkworth had a 22-year career with US headquartered, Nasdaq listed, Gilead Sciences Inc. (Gilead). During this time the company grew from a small biotech-pharmaceutical company to a multi-billion-dollar global pharmaceutical company with annual sales of over $27 billion.

During his career at Gilead, Mr. Brinkworth held several commercial, licensing, and patient access roles, including that of Executive Director - Gilead Sciences Global Patient Solutions, where he was responsible for developing and implementing comprehensive commercial and access strategies for emerging markets. He led Gilead's commercial and access operations in the Asia Pacific (APAC) where he was responsible for Gilead's branded product business, managing a geographically dispersed team and partners across 31 APAC countries including China, India, and Vietnam. During Mr. Brinkworth's career with Gilead, he completed their Senior Leadership Development Program and was recognised with multiple awards.

Mr. Brinkworth has a Bachelor's degree in Health Sciences from Edith Cowan University, and he has served on the Board of Directors of the Royal Surf Lifesaving Society of Western Australia since 2020. He is a graduate of the AICD Company Directors course and maintains active membership of the AICD.